Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1242498 | 1.00 | JUN (0.33) | JUNNFKB1NFKB2RELAALDH1A1 | |
| SCHEMBL1243541 | 0.77 | JUN (0.33) | JUNNFKB1NFKB2RELAALDH1A1 | |
| SCHEMBL27548236 | 0.72 | ADRA2A (0.52) | ALDH1A1ADRA2AADRA2BADRA2CGAA | |
| SCHEMBL6213276 | 0.71 | NOS1 (0.38) | ALDH1A1USP2RECQLADRA2AADRA2B | |
| SCHEMBL6219536 | 0.68 | ALDH1A1 (0.35) | ALDH1A1USP2RECQLGAAMAPT | |
| SCHEMBL6621084 | 0.67 | LMNA (0.33) | ALDH1A1USP2RECQL | |
| SCHEMBL2493593 | 0.67 | ALDH1A1 (0.34) | ALDH1A1USP2RECQLGAAMAPT | |
| SCHEMBL1227009 | 0.67 | ADRA2A (0.53) | ALDH1A1ADRA2AADRA2BADRA2CMAPT | |
| SCHEMBL1227007 | 0.67 | ADRA2A (0.53) | ALDH1A1ADRA2AADRA2BADRA2CMAPT | |
| SCHEMBL31200472 | 0.67 | ALDH1A1 (0.34) | ALDH1A1USP2RECQLGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884104-B2 | Such as (3R,4R)-1-Pyrimidin-4-yl-4-(2,4,5-trifluorophenyl)piperidin-3-amine bis-trifluoroacetic acid salt | MERCK SHARP & DOHME CORP. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-1796669-B1 | AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2010-09-22 | — | — | EP | disclosed |
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | JUN 3114/4885NFKB1 3040/4885NFKB2 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.